Papillary Urothelial Carcinoma of Urinary Bladder Identified on 18F-Fluciclovine PET/CT.
Meka VM, Wankhar B, Ojili V, Batchala PP.
Clin Nucl Med. 2021 Aug 1;46(8):e438-e439. doi: 10.1097/RLU.0000000000003614.
Usefulness of pT1 substaging in papillary urothelial bladder carcinoma.
Patriarca C, Hurle R, Moschini M, Freschi M, Colombo P, Colecchia M, Ferrari L, Guazzoni G, Conti A, Conti G, Lucianò R, Magnani T, Colombo R.
Diagn Pathol. 2016 Jan 20;11:6. doi: 10.1186/s13000-016-0466-6.
Clinicopathological Review of Micropapillary Urothelial Carcinoma.
Kumar D, Adeniran AJ.
Curr Oncol Rep. 2022 May;24(5):603-610. doi: 10.1007/s11912-022-01219-x. Epub 2022 Feb 24.
Papillary Urothelial Carcinoma.
Gupta S, Lipworth R, Mynderse LA.
Mayo Clin Proc. 2021 Nov;96(11):2746-2747. doi: 10.1016/j.mayocp.2021.08.022.
Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guerin immunotherapy.
Kim SJ, You D, Jeong IG, Song C, Hong B, Kim CS, Ahn H, Hong JH.
J Cancer Res Clin Oncol. 2019 Aug;145(8):2131-2140. doi: 10.1007/s00432-019-02956-6. Epub 2019 Jun 21.
Prognostic significance of minor high grade component in non-invasive papillary urothelial carcinoma of urinary bladder: (A study of 273 consecutive cases over a period of 3 years).
Syed M, Mushtaq S, Loya A, Hassan U, Mir K, Hussain M, Hameed M, Sheikh UN.
Ann Diagn Pathol. 2023 Apr;63:152079. doi: 10.1016/j.anndiagpath.2022.152079. Epub 2022 Dec 13.
Reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin for papillary carcinoma of bladder.
Singh YP, Roy D, Jois B, Shetti M.
BMJ Case Rep. 2022 Apr 13;15(4):e249208. doi: 10.1136/bcr-2022-249208.
Benign and low-grade papillary lesions of the urinary bladder: a review of the papilloma-papillary carcinoma controversy, and a report of five typical papillomas.
Eble JN, Young RH.
Semin Diagn Pathol. 1989 Nov;6(4):351-71.
Amyloidosis of the bladder and association with urothelial carcinoma: report of 29 cases.
Sirohi D, Gandhi J, Amin MB, Luthringer DJ.
Hum Pathol. 2019 Nov;93:48-53. doi: 10.1016/j.humpath.2019.08.011. Epub 2019 Aug 16.
Re: final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.
Wood DP.
J Urol. 2014 Feb;191(2):348-9. doi: 10.1016/j.juro.2013.10.133. Epub 2013 Oct 29.
